Bharat Parenterals Ltd
Bharat Parenterals Q1 FY26: Revenue ₹116.00 Cr, PAT ₹0.86 Cr
Q1 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹116Cr
- +25.4% YoY
- Net profit
- −₹1Cr
- Q1 FY25: −₹9 Cr
- Margin
- 11.88%
- +7 pp YoY
Guidance rank: #10 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Bharat Parenterals Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q1 FY 2026 Revenue from Operations (Consolidated): ₹116.00 crore, up 25.4% YoY from ₹92.51 crore in Q1 FY 2025 (Page 26). Consolidated Q1 FY26 vs Q1 FY25: - EBITDA: ₹13.78 crore, +206.9% YoY - EBITDA Margin: 11.9% (up from 4.9%) - PAT: -₹0.86 crore, improved from -₹8.85 crore (90.3% improvement) - PAT Margin: -
From Bharat Parenterals Ltd's Q1 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1 FY 2026 Revenue from Operations (Consolidated): ₹116.00 crore, up 25.4% YoY from ₹92.51 crore in Q1 FY 2025 (Page 26).
- Total Operating Revenue (Consolidated): ₹117.06 crore, up 23.2% YoY from ₹95.05 crore in Q1 FY 2025 (Page 26).
- Standalone Revenue from Operations: ₹94.37 crore, up 2.51% YoY from ₹92.06 crore in Q1 FY 2025 (Page 24).
- Standalone Total Operating Revenue: ₹95.84 crore, essentially flat YoY (-0.13%) compared to ₹95.96 crore in Q1 FY 2025 (Page 24).
- FY26 Revenue Outlook: BPL projects standalone revenue growth of 12–14% supported by strong order book and capacity utilization (Page 25).
2 more points from Bharat Parenterals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Bharat Parenterals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Innoxel Lifesciences: Capex ~₹250 crore; facility fully constructed, USFDA inspected, undergoing product validation (Page 10).
- Varenyam Bio Lifesciences: Capex till date ~₹30 crore; manufacturing facility under construction; targeted operational readiness by FY27 (Page 10).
- Expansion planned:
- Innoxel’s commercial CMO supplies expected to commence Q1 FY27 after EU-GMP inspection in FY26 (Page 25).
2 more points from Bharat Parenterals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Bharat Parenterals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Bharat Parenterals Ltd — Quarterly revenue & net profit
Bharat Parenterals Ltd Q1 FY26 results — key figures
| ₹ Cr | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 116 | 93 | +25.4% | 104 | +11.6% |
| Operating profit (EBITDA) | 14 | 4 | +206.9% | 2 | +517.9% |
| Operating margin | 11.88% | 4.85% | +7 pp | 2.14% | +9.7 pp |
| Profit before tax | 3 | -5 | — | -8 | — |
| Net profit (PAT) | -1 | -9 | — | -9 | — |
| EPS (₹) | 11.94 | 1.96 | +509.2% | -6.86 | — |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹100 Cr, net loss ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Bharat Parenterals's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences (Q1 FY26)
168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals (Q1 FY26)
Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…
- Morepen Laboratories (Q1 FY26)
Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- NGL Fine Chem (Q1 FY26)
Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Bharat Parenterals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Bharat Parenterals Ltd Q1 FY26 results?
Q1 FY 2026 Revenue from Operations (Consolidated): ₹116.00 crore, up 25.4% YoY from ₹92.51 crore in Q1 FY 2025 (Page 26). Consolidated Q1 FY26 vs Q1 FY25: - EBITDA: ₹13.78 crore, +206.9% YoY - EBITDA Margin: 11.9% (up from 4.9%) - PAT: -₹0.86 crore, improved from -₹8.85 crore (90.3% improvement) - PAT Margin: -
What is Bharat Parenterals Ltd share price analysis?
Bharat Parenterals Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,040 Cr. Investors should review the full earnings analysis for detailed insights.
Is Bharat Parenterals Ltd planning capital expenditure?
Innoxel Lifesciences: Capex ~₹250 crore; facility fully constructed, USFDA inspected, undergoing product validation (Page 10).
Keep Bharat Parenterals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.